Shared Decision-Making and Patient-Centered Care in CIDP

In "Shared Decision-Making and Patient-Centered Care in CIDP," the panelists in neurology and neuromuscular medicine explore how a collaborative, patient-centered approach shapes treatment decisions across the CIDP care journey. The discussion opens with panelists sharing their strategies for introducing treatment options to newly diagnosed patients, generally leading with an optimistic but realistic framing that effective therapies exist while acknowledging that recovery is gradual and full return to baseline is not guaranteed for all patients. Immunoglobulin therapy emerges as the most commonly chosen first-line option in practice, with many patients expressing reluctance toward corticosteroids due to concerns about side effects. Panelists note, however, that short-term corticosteroid use can be a practical bridging strategy when insurance delays impede timely immunoglobulin access in rapidly worsening patients.

A recurring theme is the critical importance of expectation-setting to preserve patient trust and support long-term adherence. Panelists emphasize explaining that immunotherapy works by halting immune-mediated nerve damage rather than directly repairing nerves, and that recovery depends on the slower biological processes of remyelination and axonal regeneration. Clarifying that tingling and pain can reflect nerve regeneration rather than disease worsening is highlighted as a particularly useful patient education point. Panelists also stress the value of encouraging physical activity and rehabilitation as complements to immunotherapy.

The episode further addresses the logistical dimensions of shared decision-making, including how medical comorbidities, infusion burden, and lifestyle considerations influence therapy selection. In diagnostically uncertain cases, initiating immunoglobulin therapy as a therapeutic trial is noted as a practical approach, given that treatment response is itself a recognized diagnostic criterion. Panelists conclude that with multiple evidence-based but non-comparatively studied options now available, shared decision-making becomes increasingly essential, and ensuring patients have full information to make lifestyle-compatible choices is paramount to treatment success.

The next episode in this series, "Long-Term Treatment Strategy and Holistic Management in CIDP," features the panelists discussing how treatment goals and strategies evolve over the long-term disease course of CIDP, addressing expectations around sustained immunotherapy, the possibility of remission, dose minimization, and the importance of integrating supportive care and general health optimization into long-term disease management.